News coverage about Spark Therapeutics (NASDAQ:ONCE) has trended somewhat positive recently, Accern reports. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9540104357514 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Spark Therapeutics (NASDAQ:ONCE) traded up 1.25% during mid-day trading on Friday, hitting $75.96. 387,417 shares of the stock traded hands. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $80.89. The stock’s market cap is $2.37 billion. The company has a 50 day moving average of $67.15 and a 200-day moving average of $59.85.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.75) by $0.14. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.04) EPS. Equities research analysts forecast that Spark Therapeutics will post ($7.49) earnings per share for the current year.

Several equities research analysts have recently weighed in on the stock. UBS AG reaffirmed a “buy” rating and issued a $92.00 price target (up previously from $70.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $89.00 price target (up previously from $69.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $60.00 to $100.00 in a research note on Tuesday. Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $92.00 price objective (up previously from $77.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $82.27.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/spark-therapeutics-nasdaqonce-receives-news-impact-score-of-0-05/1479430.html.

In other news, CFO Stephen W. Webster sold 2,337 shares of Spark Therapeutics stock in a transaction on Monday, July 31st. The shares were sold at an average price of $71.12, for a total value of $166,207.44. Following the transaction, the chief financial officer now directly owns 4,837 shares of the company’s stock, valued at approximately $344,007.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel Faga sold 3,000 shares of Spark Therapeutics stock in a transaction on Monday, July 24th. The shares were sold at an average price of $70.00, for a total transaction of $210,000.00. Following the completion of the transaction, the insider now directly owns 3,000 shares in the company, valued at $210,000. The disclosure for this sale can be found here. Insiders have sold a total of 314,310 shares of company stock valued at $21,866,838 in the last 90 days. Insiders own 7.30% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.